PROCEPT BioRobotics Announces Real-World, Long-Term Data Demonstrate Sustained Benefits Of Aquablation Therapy For Men With Benign Prostatic Hyperplasia
Portfolio Pulse from Benzinga Newsdesk
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) announced long-term, real-world data demonstrating the sustained benefits of Aquablation therapy for treating benign prostatic hyperplasia (BPH). The data, presented at the American Urological Association Annual Meeting, showed significant improvements in prostate volume, urinary flow rate, and symptom scores across multiple studies. The therapy was effective across a range of prostate sizes with a low rate of surgical retreatment, highlighting its safety and durability.
May 06, 2024 | 12:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
PROCEPT BioRobotics' announcement of positive long-term data for Aquablation therapy in treating BPH could enhance its market position and investor confidence.
The announcement of positive long-term, real-world data for Aquablation therapy positions PROCEPT BioRobotics favorably in the urology market. The therapy's demonstrated safety, efficacy, and durability in treating BPH, a common condition, could lead to increased adoption and sales. This, in turn, may positively impact PRCT's stock price in the short term as investors react to the potential for increased market share and revenue.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100